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Laboratory, Liver Unit, Hospital Clínic, Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, SpainSee Article, pages 1026–1031In a worldwide scenario of pandemic obesity and metabolic syn-
drome, non-alcoholic fatty liver disease (NAFLD) is exponentially
increasing. NAFLD per se has become the most frequent cause for
referral for chronic liver disease evaluation (CLD) and an increas-
ing cause of hepatocellular carcinoma and end-stage liver disease
requiring liver transplantation in developed countries [1,2]. Fatty
liver (steatosis) can be also found in patients with CLD of other
aetiologies, since some CLD are themselves steatogenic (chronic
hepatitis C virus – HCV infection; alcoholic liver disease), and
since the metabolic syndrome can be superimposed to other liver
diseases.
Detection of hepatic steatosis in CLD patients is relevant for
several reasons. Just to cite some, NAFLD is a well recognized
co-factor accelerating the progression of CLD [3] and reduces
the likelihood of sustained virological response in patients with
HCV [4]. Furthermore, in patients undergoing liver resection
NAFLD independently increases the risk of postoperative compli-
cations and death [5]. Finally, in the setting of liver transplanta-
tion the presence of macrovesicular steatosis in the graft
increases the 1-year risk of graft failure [6]. Therefore, an accu-
rate method to detect and quantify liver steatosis would be extre-
mely useful and as such it has been subject of research in the last
10 years.
The presence of fat within the liver tissue modiﬁes its physical
properties, making it visible by appropriate imaging techniques.
The most sensitive and most accurate imaging method to assess
fatty liver so far is magnetic resonance spectroscopy, that is able
to diagnose steatosis when involving P5% of hepatocytes [7].
Regrettably, this technique cannot be used routinely given its
high cost, and certainly it cannot be used as a point-of-care
method to guide a rapid decision making in clinical practice.Journal of Hepatology 20
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Open access under CC BY-NC-ND license.Liver ultrasound (US) is accepted as the ﬁrst line imaging
technique to screen for liver steatosis given its low cost, safety
and wide availability. US is accurate in detecting steatosis if this
involves at least 20% of hepatocytes [8], gives results in real
time and can be used as a point-of-care method, and allows
mirroring changes in hepatic fat content over time. However,
US assessment has substantial well-known limitations [7]: it
relies upon a qualitative or at most upon a semi-quantitative
assessment, it is operator-dependent (meaning that it requires
a speciﬁc expertise), and it has a limited applicability in case
of morbid obesity. Furthermore, the accuracy of US in diagnos-
ing steatosis in patients with pre-existent CLD might be
reduced by the presence of ﬁbrosis, and has not been ade-
quately assessed.
Controlled attenuation parameter (CAP) is a recently devel-
oped non-invasive technique that might overcome some of these
limitations. CAP measures the degree of ultrasound attenuation
due to hepatic fat at the standardized frequency of 3.5 MHz
taking advantage of a technology named vibration-controlled
elastography (VCTE™) implemented on FibroScan (Echosens,
Paris, France) [9]. The software provides a numerical value that
is operator-independent and can be obtained by operators
without experience in medical imaging simultaneously to LS
measurement. CAP values range from 100 to 400 dB/m, and the
ﬁnal result is the median value of 10 valid measurements (note
that CAP is calculated simultaneously with valid LS measure-
ments) [9]. CAP values correlated well with the amount of
steatosis assessed by liver biopsy in previous studies from differ-
ent countries [9–15]; values >215 dB allowed the detection of
fatty inﬁltration P10% of hepatocytes with a sensitivity over
90% in a recent study [10], while the CAP cut-off associated with
signiﬁcant steatosis (>33% of hepatocytes) varied among studies
but was invariably >250 dB [9–15]. Furthermore, CAP values were
not inﬂuenced by the presence of ﬁbrosis or cirrhosis. These
results were certainly promising, but were obtained in relatively
small, selected populations (<150 cases), preventing to conclude
what is the real applicability of the technique in detecting
steatosis, and which factors may cause uncertainty on CAP
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In this number of Journal of Hepatology, de Ledinghen and
colleagues [16] provide interesting data expanding the knowl-
edge of this new method in CLD.
CAP performance was evaluated in a large prospective study
including 5323 consecutive patients with CLD of various etiolo-
gies in whom the metabolic proﬁle and LS by FibroScan were
also estimated. A subgroup of 440 patients (of whom 52% had ste-
atosis, being this severe in 15%) simultaneously underwent liver
biopsy. In this subset CAP conﬁrmed an excellent diagnostic accu-
racy for steatosis detection, with an adjusted AUROC of 0.914
(95% CI 0.90–0.93). Taken together, the results of this [16] and
previous studies [9–15], demonstrate that CAP allows a precise
and reliable non-invasive diagnosis of liver steatosis in patients
with CLD, and indicates that a ‘‘one-shot study’’ using the same
equipment that gives results in real time can be used to diagnose
both steatosis and ﬁbrosis in this population.
CAP has the additional advantage of being quantitative. In the
whole study population, factors independently associated with
CAP values indicating signiﬁcant steatosis (>33% of hepatocytes)
were male gender, age >55 years, BMI, presence of metabolic syn-
drome, and alcohol abuse. Notably, while male gender and age
>55 years increased by about 30% the risk of showing a CAP value
of either 250–300 dB or >300 dB, obesity, metabolic syndrome
and alcohol abuse (variables epidemiologically associated with
a more severe fatty liver [17]) were more strongly associated
with values of CAP >300 dB.
LS >6 kPa was also associated with high CAP values indepen-
dent of the features of metabolic syndrome and alcohol abuse.
This ﬁnding was not further analyzed, but is somehow disturbing
since it implies either that a common factor can explain increases
in both CAP and LS (such as can occur in patients with HCV-
related CLD inducing both steatosis and ﬁbrosis) or that false
positive results of CAP might be observed in patients with
increased LS. Additional data are required to clarify this issue.
Technical failure of the method (observed in 7.7% of cases)
was also signiﬁcantly associated with age >55 years, BMI, pres-
ence of metabolic syndrome, and with female gender. These
results are not surprising considering that technical failures of
LS with the standard M FibroScan probe, that is used for CAP
measurement, occur more often in such patients [18]. Clearly, a
CAP algorithm for the FibroScan XL probe, speciﬁcally designed
for obese population, would be welcome.
Several other questions remain to be answered. The ﬁrst
regards the generalizability of the ﬁndings of de Ledinghen and
colleagues [16] to primary care population, in which it is impor-
tant to detect NAFLD since it is an independent predictor of can-
cer, cardiovascular disease, and mortality from any cause [17].
Studies targeting the general population are still scarce, but
recent data conﬁrm that CAP correlates with the features of met-
abolic syndrome in this setting [19,20].
The second question, to be addressed both in patients with
CLD and in the general population, regards which CAP cut-off
should be used to correctly identify the presence of liver steatosis
and to estimate its amount. Given the well known limitations of
liver biopsy (limited sampling of the liver, implying a risk of over-
or underestimating steatosis even with morphometric analysis),
studies comparing CAP with magnetic resonance spectroscopy,
that gives a quantitative measure of fat content in the whole liver
and is probably more accurate than biopsy [7], would be of great
value. Future studies should also focus on assessing whether CAP
is able to accurately mirror changes in steatosis over time. ThisJournal of Hepatology 201would be important to consider CAP a reliable biomarker for
assessing the effectiveness of new treatments for NAFLD in clin-
ical trials.
A ﬁnal issue regards how CAP compares with other non-inva-
sive methods available in this ﬁeld. Up to date conﬂicting results
have been obtained in studies comparing CAP to serum indices of
steatosis (Steatotest™ [BioPredictive, Paris, France], FLI and
Hepatic Steatosis Index) [10,13,16,19]. Data comparing CAP with
US in the general population are also inconclusive: although in
one study CAP was able to detect steatosis in patients with nor-
mal US, suggesting that it might be more accurate [20], in another
study both methods had a similar, good accuracy for the diagno-
sis of steatosis [19]. Analogous comparisons between these two
point-of-care methods are lacking in patients with CLD, and
should be performed in order to design diagnostic algorithms
useful to correctly and non-invasively diagnose steatosis and its
severity.Financial support
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